Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC
Multicenter Phase I/II Clinical Trial of Recombinant Human Endostatin Continued Pumping Into Vein Combining With Concurrent Chemo-Radiotherapy in the Patients With Unresectable Stage III Non-small-Cell Lung Cancer
Sponsor: Chinese Academy of Medical Sciences
This PHASE1/PHASE2 trial investigates Stage III Non-small-Cell Lung Cancer and is currently completed. Chinese Academy of Medical Sciences leads this study, which shows 9 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2022 — Oct 2023 [monthly]
Completed PHASE1_PHASE2
-
Nov 2022 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Nov 2022 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
Status: Unknown Status → Completed
-
Jan 2017 — Aug 2017 [monthly]
Unknown Status PHASE1_PHASE2
First recorded
Nov 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chinese Academy of Medical Sciences
- Fudan University
- Fujian Cancer Hospital
- Jiangsu Cancer Institute & Hospital
- Peking University Cancer Hospital & Institute
- Shandong Cancer Hospital and Institute
- The First People's Hospital of Lianyungang
- Tianjin Medical University Cancer Institute and Hospital
- Zhejiang Cancer Hospital
For direct contact, visit the study record on ClinicalTrials.gov .